Is This Heavily Shorted Biotech Stock a Good Contrarian Buy?
Short-sellers have piled into Adaptimmune Therapeutics and MannKind Corp. this year. Could these two biotechs represent good contrarian buys for the long-term investor?
Stocks To Watch in Orphan Drugs
Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.
Here's What Caused Sarepta Therapeutics Inc. to More Than Double in May
Sarepta Therapeutics rockets higher by triple-digits in May following an update on the development of its lead drug eteplirsen. Find out what announcement had Wall Street and investors clamoring to buy its stock and whether or not it's still worth buying.